Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
March 2021
-
Ad hoc release
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed… -
Featured News
EPIS explores how COVID-19 is shaping the future of digital engagement within healthcare
Patient community representatives call for improved digital health literacy, standardised digital platforms, and co-creation of digital solutions.
-
Story People and Culture
Challenging a young scientist to focus on patients
Novartis researcher Joana Silva had a life-changing experience with a mentor.
-
Story People and Culture
Teaching a daughter the power of purpose
Racey Muchilwa, Head of Sub-Saharan Africa for Novartis, reflects on her mother’s calling as a teacher.
-
Story People and Culture
Inspiring a daughter to make her own path
Chief Talent and People Solutions Officer Tripti Jha’s mother prioritized her learning in a rural region of India with limited opportunities for girls.
-
Ad hoc release
Novartis announces change to the Executive Committee
Shannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021Thomas Kendris appointed Chief Legal Officer ad interimBasel, March 5, 2021 — Novartis announced today that Shannon Thyme… -
Press release
Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
Novartis to support global supply of another COVID-19 vaccine, leveraging manufacturing capacity and capabilities to help address pandemic.Novartis plans to manufacture the mRNA and bulk drug product… -
Press release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg… -
Press release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelle
Les actionnaires approuvent la 24e augmentation consécutive du dividende qui passe à CHF 3.– (+1,7%) par action pour l’année 2020, soit un rendement de 3,8%1 et une distribution du free cash-… -
Press release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg… -
Press release
Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gut
Die Aktionäre bewilligen die 24. Dividendenerhöhung in Folge. Für 2020 wird die Dividende auf CHF 3.00 (+1,7%) je Aktie erhöht, was einer Rendite von 3,8%1 und einem Anteil des freien… -
Press release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelle
Les actionnaires approuvent la 24e augmentation consécutive du dividende qui passe à CHF 3.– (+1,7%) par action pour l’année 2020, soit un rendement de 3,8%1 et une distribution du free cash-…